Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma.
OBJECTIVE
To evaluate the efficacy of transcatheter arterial chemoembolization (TACE) using a suspension of a fine-powder formulation of cisplatin (DDPH) for hepatocellular carcinoma (HCC).


METHODS
The study population was comprised of 164 patients who were treated by TACE alone. Of these patients, 76 underwent TACE using a suspension of DDPH in lipiodol (LPD) (DDPH group), and the remaining 88 underwent TACE with an emulsion of doxorubicin (ADM) with LPD (ADM group). We compared the DDPH group with the ADM group in terms of the objective early response rate, progression free survival (PFS) and overall survival (OS).


RESULTS
The objective early response rate in the DDPH group was significantly higher than that in the ADM group (54% vs 24%, P < 0.001). The PFS rate in the DDPH group was also significantly higher than that in the ADM group (P < 0.001). Moreover, the OS in the DDPH group was significantly longer than that in the ADM group (P = 0.002). Although the incidence rate of nausea or vomiting in the DDPH group was higher than that in the ADM group, the ADM group showed a higher incidence rate of the adverse events of hepatic arterial damage and leucopenia. No other serious complications were observed in either group.


CONCLUSIONS
We conclude that TACE using a suspension of DDPH in LPD could be a useful treatment for HCC.
Kasai
Kazuhiro
K
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Uchimaru 19-1, Morioka, Iwate 020-8505, Japan. kaz-k@yc4.so-net.ne.jp
Ushio
Akira
A
Sawara
Kei
K
Miyamoto
Yasuhiro
Y
Kasai
Yukiho
Y
Oikawa
Kanta
K
Kuroda
Hidekatsu
H
Takikawa
Yasuhiro
Y
Suzuki
Kazuyuki
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D018572:Disease-Free Survival; D004304:Dosage Forms; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011208:Powders; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D004304:Dosage Forms; D011208:Powders; D002945:Cisplatin